by Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso GM, Jolivet P, Abdrasuliev T, Moe S, Aw PS, Samieva N, Nyang'wa BT. Lancet Global Health 2025;13(2):e355-e363. doi: 10.1016/s2214-109x(24)00467-4.
Summary: The authors of this manuscript assessed whether implementing BPaL (bedaquiline, pretomanid, and linezolid)-based regimens for tuberculosis would save costs, using data collected from the TB-PRACTECAL trial. They collected detailed primary unit cost data from health structures and collected data on patient-incurred costs from 73 participants. BPaL-based regimens averted a mean of 1.28 disability-adjusted life-years and saved a mean of 14,868 USD (SD 291) per person from the provider perspective, compared with standard-of-care regimens over 20 years, while patient-incurred costs were reduced by a mean of 172 USD (SD 0.84), this was mainly driven by the length of the inpatient period duration. Implementation of BPaL-based regimens in countries with a high tuberculosis burden could free up resources within the health system.
